pSivida Corp
(NASDAQ: PSDV)
3.84
+0.12+3.23%Today's Close
|
3.84
unch
After hours
+0.12+3.23%Today's Close
|
3.84
unch
After hours
MORE ON PSDV
COMPANY INFORMATION
| Exchange: | NASDAQ national market |
| Stock: | pSivida Ltd. |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Employees: | 29 |
DESCRIPTION
| PSivida Corp. was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert™ and BioSilicon™. It currently has three approved products and two principal product candidates under development, which represent successive generations of its Durasert technology platform. It have developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). Its most recently approved product, ILUVIEN®, is an injectable, sustained-release micro-insert delivering the corticosteroid fluocinolone acetonide (FAc) over a period of up to 3 years for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.1 million people in these seven countries have diabetes, of which Alimera has estimated that approximately 1.1 million suffer from vision loss associated with DME. Alimera has announced its intention to proceed with the direct commercialization of ILUVIEN in Germany, the U.K. and France in 2013. It is pursuing the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (posterior uveitis) as another indication for the same injectable micro-insert used in ILUVIEN. It did not license this indication to Alimera. It are also developing a bioerodible, injectable micro-insert delivering latanoprost (the Latanoprost Product) to treat glaucoma and ocular hypertension. Its primary technology systems are Durasert and BioSilicon. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The major averages ended higher across the board as the S&P 500 advanced 0.8%. Equities climbed steadily since the opening bell as investors prepared for tomorrow's policy decision from the Federal Reserve. Although chatter in recent w
...
More
MORE MARKET NEWS
Sponsored by: